Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.74 |
| ▸ | MGLL | Q99685 | 6/20 | 0.74 |
| ▸ | ABHD16A | O95870 | 2/20 | 0.68 |
| ▸ | LPL | P06858 | 1/20 | 0.50 |
| ▸ | LIPC | P11150 | 1/20 | 0.50 |
| ▸ | LIPE | Q05469 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11620781 | 0.91 | FAAH (0.78) | FAAHMGLLABHD16ALPLLIPC | |
| SCHEMBL6552790 | 0.87 | MGLL (0.74) | FAAHMGLLABHD16ALIPCLIPE | |
| SCHEMBL6552566 | 0.85 | MGLL (1.00) | FAAHMGLLABHD16A | |
| SCHEMBL2235103 | 0.83 | ABHD16A (0.74) | FAAHMGLLABHD16ALPLLIPC | |
| SCHEMBL2853740 | 0.82 | MGLL (0.66) | FAAHMGLLABHD16A | |
| SCHEMBL2233598 | 0.81 | ABHD16A (0.72) | FAAHMGLLABHD16ALPLLIPC | |
| SCHEMBL7046228 | 0.81 | ABHD16A (0.72) | FAAHMGLLABHD16ALPLLIPC | |
| SCHEMBL2233406 | 0.81 | ABHD16A (0.72) | FAAHMGLLABHD16ALPLLIPC | |
| SCHEMBL7578034 | 0.78 | ABHD16A (0.68) | FAAHMGLLABHD16ALPLLIPC | |
| SCHEMBL6551089 | 0.78 | ABHD16A (0.67) | FAAHMGLLABHD16ALPLLIPC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1482929-A1 | USE OF SUBSTITUTED 3-PHENYL-5-ALKOXY-1,3,4-OXDIAZOLE-2-ONE FOR PRODUCING MEDICAMENTS THAT INHIBIT PANCREATIC LIPASE | Aventis Pharma Deutschland GmbH (DE) | 2004-12-08 | — | — | EP | disclosed |
| US-20030236288-A1 | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-12-25 | — | — | US | disclosed |
| EP-1214302-B1 | SUBSTITUTED 3-PHENYL-5-ALKOXI-1,3,4-OXDIAZOL-2-ONES AND THEIR USE AS LIPASE INHIBITORS | AVENTIS PHARMA GMBH (DE) | 2003-10-29 | — | — | EP | disclosed |
| WO-2003072098-A1 | USE OF SUBSTITUTED 3-PHENYL-5-ALKOXY-1,3,4-OXDIAZOLE-2-ONE FOR PRODUCING MEDICAMENTS THAT INHIBIT PANCREATIC LIPASE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-09-04 | — | — | WO | disclosed |
| US-6596742-B1 | Inhibitory effect on the hormone-sensitive lipase, HSL. insecticides, controlling metabolism and multistage synthesis | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-07-22 | — | — | US | disclosed |
| EP-1214302-A1 | SUBSTITUTED 3-PHENYL-5-ALKOXI-1,3,4-OXDIAZOL-2-ONES AND THEIR USE AS LIPASE INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001017981-A1 | SUBSTITUTED 3-PHENYL-5-ALKOXI-1,3,4-OXDIAZOL-2-ONES AND THEIR USE AS LIPASE INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236288-A1 | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase | PNLIP, CEL, LIPE | FAAH 142/4885MGLL 10/4885ABHD16A 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.